These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23415804)

  • 21. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes.
    Desmares M; Delphin M; Chardès B; Pons C; Riedinger J; Michelet M; Rivoire M; Verrier B; Salvetti A; Lucifora J; Durantel D
    Antiviral Res; 2022 Oct; 206():105386. PubMed ID: 35963549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
    Bam RA; Hansen D; Irrinki A; Mulato A; Jones GS; Hesselgesser J; Frey CR; Cihlar T; Yant SR
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
    Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
    J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.
    Herschke F; Li C; Zhu R; Han Q; Wu Q; Lu Q; Barale-Thomas E; De Jonghe S; Lin TI; De Creus A
    Antiviral Res; 2021 Dec; 196():105196. PubMed ID: 34718044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
    Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
    J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STING agonists induce an innate antiviral immune response against hepatitis B virus.
    Guo F; Han Y; Zhao X; Wang J; Liu F; Xu C; Wei L; Jiang JD; Block TM; Guo JT; Chang J
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1273-81. PubMed ID: 25512416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
    Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
    AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
    Gane EJ; Dunbar PR; Brooks AE; Zhang F; Chen D; Wallin JJ; van Buuren N; Arora P; Fletcher SP; Tan SK; Yang JC; Gaggar A; Kottilil S; Tang L
    J Hepatol; 2023 Mar; 78(3):513-523. PubMed ID: 38133554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
    Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
    Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
    Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
    Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toll-like receptor 7 agonist, GS-986, is an immune-stimulant inducing follicular helper T cells and expanding HBs antigen-specific B cells in vitro.
    Mori T; Yoshio S; Yoshikawa S; Tsustui Y; Sakata T; Yoshida Y; Sakamoto Y; Kawai H; Osawa Y; Yamazoe T; Aoki Y; Fletcher SP; Kanto T
    Liver Int; 2023 Jun; 43(6):1213-1224. PubMed ID: 37029645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
    Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
    Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen.
    Sällberg M; Hughes J; Javadian A; Ronlov G; Hultgren C; Townsend K; Anderson CG; O'Dea J; Alfonso J; Eason R; Murthy KK; Jolly DJ; Chang SM; Mento SJ; Milich D; Lee WT
    Hum Gene Ther; 1998 Aug; 9(12):1719-29. PubMed ID: 9721082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.